TY - JOUR
T1 - Revolutionizing GPCR-ligand predictions
T2 - DeepGPCR with experimental validation for high-precision drug discovery
AU - Zhang, Haiping
AU - Fan, Hongjie
AU - Wang, Jixia
AU - Hou, Tao
AU - Saravanan, Konda Mani
AU - Xia, Wei
AU - Kan, Hei Wun
AU - Li, Junxin
AU - Zhang, John Z.H.
AU - Liang, Xinmiao
AU - Chen, Yang
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Oxford University Press.
PY - 2024/7/1
Y1 - 2024/7/1
N2 - G-protein coupled receptors (GPCRs), crucial in various diseases, are targeted of over 40% of approved drugs. However, the reliable acquisition of experimental GPCRs structures is hindered by their lipid-embedded conformations. Traditional protein-ligand interaction models falter in GPCR-drug interactions, caused by limited and low-quality structures. Generalized models, trained on soluble protein-ligand pairs, are also inadequate. To address these issues, we developed two models, DeepGPCR_BC for binary classification and DeepGPCR_RG for affinity prediction. These models use non-structural GPCR-ligand interaction data, leveraging graph convolutional networks and mol2vec techniques to represent binding pockets and ligands as graphs. This approach significantly speeds up predictions while preserving critical physical-chemical and spatial information. In independent tests, DeepGPCR_BC surpassed Autodock Vina and Schrödinger Dock with an area under the curve of 0.72, accuracy of 0.68 and true positive rate of 0.73, whereas DeepGPCR_RG demonstrated a Pearson correlation of 0.39 and root mean squared error of 1.34. We applied these models to screen drug candidates for GPR35 (Q9HC97), yielding promising results with three (F545-1970, K297-0698, S948-0241) out of eight candidates. Furthermore, we also successfully obtained six active inhibitors for GLP-1R. Our GPCR-specific models pave the way for efficient and accurate large-scale virtual screening, potentially revolutionizing drug discovery in the GPCR field.
AB - G-protein coupled receptors (GPCRs), crucial in various diseases, are targeted of over 40% of approved drugs. However, the reliable acquisition of experimental GPCRs structures is hindered by their lipid-embedded conformations. Traditional protein-ligand interaction models falter in GPCR-drug interactions, caused by limited and low-quality structures. Generalized models, trained on soluble protein-ligand pairs, are also inadequate. To address these issues, we developed two models, DeepGPCR_BC for binary classification and DeepGPCR_RG for affinity prediction. These models use non-structural GPCR-ligand interaction data, leveraging graph convolutional networks and mol2vec techniques to represent binding pockets and ligands as graphs. This approach significantly speeds up predictions while preserving critical physical-chemical and spatial information. In independent tests, DeepGPCR_BC surpassed Autodock Vina and Schrödinger Dock with an area under the curve of 0.72, accuracy of 0.68 and true positive rate of 0.73, whereas DeepGPCR_RG demonstrated a Pearson correlation of 0.39 and root mean squared error of 1.34. We applied these models to screen drug candidates for GPR35 (Q9HC97), yielding promising results with three (F545-1970, K297-0698, S948-0241) out of eight candidates. Furthermore, we also successfully obtained six active inhibitors for GLP-1R. Our GPCR-specific models pave the way for efficient and accurate large-scale virtual screening, potentially revolutionizing drug discovery in the GPCR field.
KW - GLP-1R
KW - GPCR
KW - GPR35
KW - drug screening
KW - graph convolutional network
UR - http://www.scopus.com/inward/record.url?scp=85196065489&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85196065489&partnerID=8YFLogxK
U2 - 10.1093/bib/bbae281
DO - 10.1093/bib/bbae281
M3 - Article
AN - SCOPUS:85196065489
SN - 1467-5463
VL - 25
JO - Briefings in Bioinformatics
JF - Briefings in Bioinformatics
IS - 4
M1 - bbae281
ER -